Biotechnology First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P – Elicio Therapeutics (NASDAQ:ELTX) Read more
Biotechnology Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics’ AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002 – Elicio Therapeutics (NASDAQ:ELTX) Read more
